This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Prevention of immunogenicity to therapeutic proteins by co-treatment with <i>O</i> -phospho-L-serine (OPLS)	Cell culture and mouse studies suggest OPLS could prevent immunogenicity against protein therapeutics. In a mouse model of hemophilia A, pretreatment with factor VIII plus OPLS decreased the antibody response induced by a subsequent factor VIII challenge compared with factor VIII plus dexamethasone pretreatment. In hemophilia A model mice, injection with dendritic cells cultured with factor VIII plus OPLS resulted in lower serum levels of anti-factor VIII antibodies than injection of dendritic cells cultured with factor VIII alone. Next steps include studies to assess OPLS in combination with other therapeutic proteins and clinical testing. OPLS is a research compound.	Patented; available for licensing and partnering	Fathallah, A.M. <i>et al. J. Pharm. Sci.</i> ; published online Sept. 29, 2014; doi:10.1002/jps.24173 Contact: Sathy V. Balu-Iyer, University at Buffalo, Buffalo, N.Y. e-mail: svb@buffalo.edu
	SciBX 7(41); doi:10.1038/scibx.2014.1219 Published online Oct. 23, 2014		